Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10154529 | 0.73 | BACE1 (0.49) | BACE1 | |
| SCHEMBL48673 | 0.63 | BACE1 (0.39) | ALDH1A1LMNABACE1RAB9A | |
| SCHEMBL10157161 | 0.62 | BACE1 (0.71) | BACE1 | |
| SCHEMBL7227231 | 0.59 | POLB (0.53) | ALDH1A1LMNASMN1; SMN2KMT2ANPC1 | |
| SCHEMBL3610038 | 0.57 | TAAR1 (0.71) | — | |
| SCHEMBL3610035 | 0.57 | TAAR1 (0.71) | — | |
| SCHEMBL12410768 | 0.56 | PTK2 (0.52) | ALDH1A1LMNAALOX15SMN1; SMN2MAPK1 | |
| SCHEMBL19554856 | 0.55 | CHRNA1 (0.36) | ALDH1A1LMNAMAPK1KMT2ASLC6A4 | |
| SCHEMBL435094 | 0.55 | SLC6A4 (0.44) | LMNAMAPK1KMT2ASLC6A4SLC6A3 | |
| SCHEMBL2084071 | 0.55 | MAPK1 (0.46) | LMNAMAPK1KMT2ASLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2597087-B1 | Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors | SHIONOGI & CO (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-20150210680-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210680-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2015-07-30 | — | — | US | disclosed |
| US-9029358-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2015-05-12 | — | — | US | disclosed |
| US-9029358-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2015-05-12 | — | — | US | disclosed |
| US-8895548-B2 | Pharmaceutical composition for treating alzheimer's disease | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895548-B2 | Pharmaceutical composition for treating alzheimer's disease | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8815851-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8815851-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| EP-1942105-B1 | AMINODIHYDROTHIAZINE DERIVATIVE | SHIONOGI & CO (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-20130158260-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2013-06-20 | — | — | US | disclosed |
| US-8173642-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173642-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20120022249-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120016116-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120016116-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20100160290-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160290-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20090082560-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082560-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016116-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | ALDH1A1 1897/4885LMNA 3251/4885ALOX15 1186/4885 |
| US-20100160290-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | NR1H2, NR1H3, NR0B1 | ALDH1A1 2485/4885LMNA 1970/4885ALOX15 1428/4885 |
| US-20130158260-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | ALDH1A1 1242/4885LMNA 2737/4885ALOX15 1198/4885 |
| US-20120022249-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | ALDH1A1 1897/4885LMNA 3251/4885ALOX15 1186/4885 |
| US-20150210680-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | ALDH1A1 1897/4885LMNA 3251/4885ALOX15 1186/4885 |
| US-20090082560-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | ALDH1A1 1897/4885LMNA 3251/4885ALOX15 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.